(NASDAQ: AGEN) Agenus's forecast annual revenue growth rate of 9.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Agenus's revenue in 2026 is $106,829,000.On average, 5 Wall Street analysts forecast AGEN's revenue for 2026 to be $6,227,268,785, with the lowest AGEN revenue forecast at $3,688,545,533, and the highest AGEN revenue forecast at $8,284,433,816. On average, 5 Wall Street analysts forecast AGEN's revenue for 2027 to be $4,196,970,350, with the lowest AGEN revenue forecast at $3,642,634,261, and the highest AGEN revenue forecast at $4,892,101,004.
In 2028, AGEN is forecast to generate $5,220,961,738 in revenue, with the lowest revenue forecast at $3,112,852,201 and the highest revenue forecast at $8,395,301,034.